VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASCO 2020 | Glasdegib in combination with azacitidine in MDS, AML and CMML

Amer Zeidan, MBBS, MHS, of Yale University and Yale Cancer Center, New Haven, CT, discusses the use of of glasdegib, a Hedgehog pathway inhibitor, in combination with azacitidine in patients with untreated higher-risk myelodysplastic syndromes, acute myeloid leukemia and chronic myelomonocytic leukemia. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter